Investigación en terapias específicas de mutación metabólicas hereditarias

Tesis doctoral inédita. Universidad Autónoma de Madrid, Facultad de Ciencias, Departamento de Biología Molecular. Fecha de lectura: 14-04-08

Detalles Bibliográficos
Autor: Aguado, Cristina
Tipo de recurso: tesis doctoral
Fecha de publicación:2008
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/8049
Acceso en línea:http://hdl.handle.net/10261/8049
Access Level:acceso abierto
Palabra clave:Enfermedades hereditarias metabólicas
id ES_68e353834cdcb8ba2ecaaeae29b17a2e
oai_identifier_str oai:digital.csic.es:10261/8049
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Investigación en terapias específicas de mutación metabólicas hereditarias
title Investigación en terapias específicas de mutación metabólicas hereditarias
spellingShingle Investigación en terapias específicas de mutación metabólicas hereditarias
Aguado, Cristina
Enfermedades hereditarias metabólicas
title_short Investigación en terapias específicas de mutación metabólicas hereditarias
title_full Investigación en terapias específicas de mutación metabólicas hereditarias
title_fullStr Investigación en terapias específicas de mutación metabólicas hereditarias
title_full_unstemmed Investigación en terapias específicas de mutación metabólicas hereditarias
title_sort Investigación en terapias específicas de mutación metabólicas hereditarias
dc.creator.none.fl_str_mv Aguado, Cristina
author Aguado, Cristina
author_facet Aguado, Cristina
author_role author
dc.contributor.none.fl_str_mv Ruiz, Lourdes
dc.subject.none.fl_str_mv Enfermedades hereditarias metabólicas
topic Enfermedades hereditarias metabólicas
description Tesis doctoral inédita. Universidad Autónoma de Madrid, Facultad de Ciencias, Departamento de Biología Molecular. Fecha de lectura: 14-04-08
publishDate 2008
dc.date.none.fl_str_mv 2008
2008
2008
dc.type.none.fl_str_mv info:eu-repo/semantics/doctoralThesis
http://purl.org/coar/resource_type/c_db06
format doctoralThesis
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/8049
url http://hdl.handle.net/10261/8049
dc.language.none.fl_str_mv Español
language_invalid_str_mv Español
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 1832675 bytes
application/pdf
dc.publisher.none.fl_str_mv Universidad Autónoma de Madrid
publisher.none.fl_str_mv Universidad Autónoma de Madrid
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869409992054931456
spelling Investigación en terapias específicas de mutación metabólicas hereditariasAguado, CristinaEnfermedades hereditarias metabólicasTesis doctoral inédita. Universidad Autónoma de Madrid, Facultad de Ciencias, Departamento de Biología Molecular. Fecha de lectura: 14-04-08In this work, we have investigated specific mutation therapies in metabolic genetic diseases, specifically we have analyzed the mechanisms underlying cofactor and coenzyme responsiveness in phenylketonuria (PKU), propionic acidemia (PA), methylcrotonylglycinuria (MCG) and methylmalonic aciemia (MMA) and splicing therapies in PA. We have identified the mutations present in Spanish PKU patients who respond to BH4 and we have selected some mutations associated to responsiveness for expression analysis. We have analyzed in total 14 missense mutations using different prokaryote, eukaryote and cell‐free systems. Five mutations were expressed in vitro in E.coli as MBP‐PAH fusion proteins, we have determined PAH steady‐state kinetic properties in order to detect possible defects in BH4 affinity. The majority of the mutations affected kinetic and regulatory properties. Only one mutation showed slightly reduced affinity for the cofactor under steady‐state conditions. We have also measured the degradation rates of 11 mutant PAH proteins expressed in a cell‐free system, using pulse‐chase analysis and presence or absence of BH4 and determined the amount of three of the mutant proteins after transfection in Hep3B as FLAG‐PAH fusion proteins in presence of different levels of BH4. The results show that high concentrations of BH4 protect some mutant proteins against degradation and result in an increase in the steady‐state amounts of protein in hepatoma cells. In the hepatoma cellular model, BH4 levels don’t affect the expression of the PAH gene. In MMA cblB type we have selected two mutations previously associated with responsiveness to OHcobalamin. We have expressed the ATR protein in E. coli to determine steady‐state kinetic properties in order to detect possible defects in cobalamin affinity. The results suggest a stability defect for one of the mutant proteins, with reduced enzymatic activity but with K(m) for ATP and Kd for cob(I)alamin similar to wild‐type values. The last coenzyme analyzed in this work was biotin, for which there is no consensus in the literature if it affects the expression of biotin‐dependent carboxylases. In Hep3B cells we have analyzed the effect of different levels of biotin in the activity, amount of functional active protein and mRNA levels of two carboxylases, PCC and MCC, that when defective cause PA and MCG, respectively. In our model, biotin does not affect the expression of the enzymes but favours the conversion of apocarboxylase to holocarboxylase. Finally, we describe the use of antisense morpholino oligonucleotides (AMOs) to restore normal splicing caused by intronic molecular defects identified in PA. The two point mutations described in deep intronic regions increase the splicing score of pseudoexonic regions or generate consensus binding motifs for splicing factors, such as SRp40, which favour the intronic inclusion in PCCA (r.1284ins84) and PCCB (r.654ins72) mRNAs. AMOs were targeted to the 5´ and 3´ cryptic splice sites of the pseudoexons to block the access of the splicing machinery. Using this antisense therapeutics, we have obtained correctly spliced mRNA that was efficiently translated and PCC activities were rescued in patients´fibroblasts. Our results demonstrate that the aberrant inclusions of the intronic sequences are disease‐causing mutations in these patients and that the use of AMOs is an effective therapeutic strategy in this genetic disorder.El presente trabajo ha sido realizado en el laboratorio de la Prof. Magdalena Ugarte, Catedrática del Departamento de Biología Molecular, en el Centro de Biología Molecular “Severo Ochoa” de la Universidad Autónoma de Madrid, y durante una estancia breve en el laboratorio de la Prof. Ruma Banerjee, en el Centro Redox de Biología, Departamento de Bioquímica, en la Universidad de Nebraska, EEUU, con la ayuda de una beca predoctoral concedida por el ministerio de Educación y Ciencia.Peer reviewedUniversidad Autónoma de MadridRuiz, Lourdes200820082008info:eu-repo/semantics/doctoralThesishttp://purl.org/coar/resource_type/c_db061832675 bytesapplication/pdfhttp://hdl.handle.net/10261/8049reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Españolinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/80492026-05-22T06:33:51Z
score 15,811543

Similares en LA Referencia